These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10975874)

  • 21. Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons.
    Petersén A; Castilho RF; Hansson O; Wieloch T; Brundin P
    Brain Res; 2000 Feb; 857(1-2):20-9. PubMed ID: 10700549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid.
    Beal MF; Brouillet E; Jenkins BG; Ferrante RJ; Kowall NW; Miller JM; Storey E; Srivastava R; Rosen BR; Hyman BT
    J Neurosci; 1993 Oct; 13(10):4181-92. PubMed ID: 7692009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration.
    Mittoux V; Ouary S; Monville C; Lisovoski F; Poyot T; Conde F; Escartin C; Robichon R; Brouillet E; Peschanski M; Hantraye P
    J Neurosci; 2002 Jun; 22(11):4478-86. PubMed ID: 12040055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat.
    Brouillet E; Guyot MC; Mittoux V; Altairac S; Condé F; Palfi S; Hantraye P
    J Neurochem; 1998 Feb; 70(2):794-805. PubMed ID: 9453576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease.
    Park JE; Lee ST; Im WS; Chu K; Kim M
    Neurosci Lett; 2008 Dec; 448(1):143-7. PubMed ID: 18938211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain.
    Bizat N; Galas MC; Jacquard C; Boyer F; Hermel JM; Schiffmann SN; Hantraye P; Blum D; Brouillet E
    Neuropharmacology; 2005 Oct; 49(5):695-702. PubMed ID: 15998526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid.
    Guyot MC; Hantraye P; Dolan R; Palfi S; Maziére M; Brouillet E
    Neuroscience; 1997 Jul; 79(1):45-56. PubMed ID: 9178864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of cytosolic and mitochondrial Ca2+, ATP, mitochondrial membrane potential, and calpain activity on the mechanism of neuron death induced by 3-nitropropionic acid.
    Nasr P; Gursahani HI; Pang Z; Bondada V; Lee J; Hadley RW; Geddes JW
    Neurochem Int; 2003 Jul; 43(2):89-99. PubMed ID: 12620277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF.
    Puerta E; Hervias I; Barros-Miñones L; Jordan J; Ricobaraza A; Cuadrado-Tejedor M; García-Osta A; Aguirre N
    Neurobiol Dis; 2010 May; 38(2):237-45. PubMed ID: 20109548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo.
    Yang L; Sugama S; Mischak RP; Kiaei M; Bizat N; Brouillet E; Joh TH; Beal MF
    Neurobiol Dis; 2004 Nov; 17(2):250-9. PubMed ID: 15474362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways.
    Lee ST; Chu K; Park JE; Hong NH; Im WS; Kang L; Han Z; Jung KH; Kim MW; Kim M
    J Neurochem; 2008 Mar; 104(5):1190-200. PubMed ID: 17976163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington's disease.
    Yu Z; Zhou D; Cheng G; Mattson MP
    J Mol Neurosci; 2000 Aug; 15(1):31-44. PubMed ID: 11211235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
    Lastres-Becker I; de Miguel R; De Petrocellis L; Makriyannis A; Di Marzo V; Fernández-Ruiz J
    J Neurochem; 2003 Mar; 84(5):1097-109. PubMed ID: 12603833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes.
    Rossignol J; Boyer C; Lévèque X; Fink KD; Thinard R; Blanchard F; Dunbar GL; Lescaudron L
    Behav Brain Res; 2011 Mar; 217(2):369-78. PubMed ID: 21070819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3-nitropropionic acid-induced mitochondrial permeability transition: comparative study of mitochondria from different tissues and brain regions.
    Mirandola SR; Melo DR; Saito A; Castilho RF
    J Neurosci Res; 2010 Feb; 88(3):630-9. PubMed ID: 19795369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dihydromyricetin Ameliorates 3NP-induced Behavioral Deficits and Striatal Injury in Rats.
    Mu S; Li Y; Liu B; Wang W; Chen S; Wu J; OuYang L; Zhu Y; Li K; Zhan M; Liu Z; Jia Y; Ma Y; Lei W
    J Mol Neurosci; 2016 Oct; 60(2):267-75. PubMed ID: 27501707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies.
    Ouary S; Bizat N; Altairac S; Ménétrat H; Mittoux V; Condé F; Hantraye P; Brouillet E
    Neuroscience; 2000; 97(3):521-30. PubMed ID: 10828534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease.
    Kodsi MH; Swerdlow NR
    Neurosci Lett; 1997 Aug; 231(2):103-7. PubMed ID: 9291151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Participation of par-4 in the degeneration of striatal neurons induced by metabolic compromise with 3-nitropropionic acid.
    Duan W; Guo Z; Mattson MP
    Exp Neurol; 2000 Sep; 165(1):1-11. PubMed ID: 10964480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.
    Kraft JC; Osterhaus GL; Ortiz AN; Garris PA; Johnson MA
    Neuroscience; 2009 Jul; 161(3):940-9. PubMed ID: 19362126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.